SOPHiA GENETICS Reports Third Quarter 2026 Results
BOSTON and ROLLE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Revenue was $24.3 million,...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 114 stories mentioning NOV, the earliest published 19 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.